Literature DB >> 25333737

Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis.

A H James1, B A Konkle, P Kouides, M V Ragni, B Thames, S Gupta, S Sood, S K Fletcher, C S Philipp.   

Abstract

The aim of this study was to elucidate the fall in von Willebrand factor (VWF) and factor VIII activity (FVIII) after childbirth in women with and without von Willebrand disease (VWD). VWF:RCo, VWF:Ag, and FVIII were obtained in the third trimester of pregnancy, on admission for childbirth, and 10 times postpartum. Specimens were processed within 4 h and analysed centrally. Means were calculated at each time point. Forty women (40 pregnancies) without VWD and 32 women (35 pregnancies) with VWD were enrolled. 15/32 with VWD were treated (30% of those with type 1 and all of those with type 2) in 17 pregnancies. Treatments prior to delivery consisted of desmopressin (2/17), VWF concentrate (15/17) and after delivery VWF concentrate (16/17). Duration of treatment was 0-21 days (median 6). VWF levels peaked at 250% of baseline--4 h postpartum in women with VWD and 12 h postpartum in women without VWD. Thereafter, VWF levels fell rapidly, approached baseline at 1 week and reached baseline at 3 weeks. Except immediately postpartum, when the levels among treated cases were higher, levels among women with VWD appeared to parallel, but were lower than those among women without VWD. Levels were lowest among those who received treatment. VWF levels fall rapidly after childbirth. Except immediately postpartum, current treatment strategies do not raise VWF levels to the levels of women without VWD or even to the levels of women with milder, untreated VWD. Consequently, women with VWD may be at risk of postpartum haemorrhage despite treatment.
© 2014 The Authors. Haemophilia Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  factor VIII; postpartum haemorrhage; pregnancy; von Willebrand disease; von Willebrand factor

Mesh:

Substances:

Year:  2014        PMID: 25333737     DOI: 10.1111/hae.12568

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  21 in total

1.  Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.

Authors:  Peter A Kouides
Journal:  Blood Adv       Date:  2017-04-25

2.  Blood volume-based von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease.

Authors:  Margaret V Ragni
Journal:  Blood Adv       Date:  2017-04-25

3.  Blood type association with bleeding outcomes at delivery in a large multi-center study.

Authors:  Najeebah A Bade; Jamil M Kazma; Richard L Amdur; Julia Ellis-Kahana; Homa K Ahmadzia
Journal:  J Thromb Thrombolysis       Date:  2020-08       Impact factor: 2.300

4.  ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.

Authors:  Nathan T Connell; Veronica H Flood; Romina Brignardello-Petersen; Rezan Abdul-Kadir; Alice Arapshian; Susie Couper; Jean M Grow; Peter Kouides; Michael Laffan; Michelle Lavin; Frank W G Leebeek; Sarah H O'Brien; Margareth C Ozelo; Alberto Tosetto; Angela C Weyand; Paula D James; Mohamad A Kalot; Nedaa Husainat; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12

5.  Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the hematologist's view.

Authors:  Margaret V Ragni
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the obstetrician's view.

Authors:  Andra H James
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 7.  Congenital and acquired bleeding disorders in pregnancy.

Authors:  Terry B Gernsheimer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 8.  Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy.

Authors:  Ozlem Turan; Rezan Abdul Kadir
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

9.  Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease.

Authors:  Nicoletta Machin; Margaret V Ragni
Journal:  Blood Adv       Date:  2020-07-28

10.  Significant gynecological bleeding in women with low von Willebrand factor levels.

Authors:  Michelle Lavin; Sonia Aguila; Niall Dalton; Margaret Nolan; Mary Byrne; Kevin Ryan; Barry White; Niamh M O'Connell; Jamie M O'Sullivan; Jorge Di Paola; Paula D James; James S O'Donnell
Journal:  Blood Adv       Date:  2018-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.